Please login to the form below

Not currently logged in
Email:
Password:

Positive opinion for Zevalin

Bayer Schering Pharma AG announced on March 20 that the European Committee for Medicinal Products for Human Use gave a positive opinion for its drug Zevalin
Bayer Schering Pharma AG announced on March 20 that the European Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for its drug Zevalin.

Pending a favourable review from the European Commission, Zevalin could receive marketing authorisation for all EU member states later this year.

Zevalin (ibritumomab tiuxetan) has been developed as a consolidation therapy for patients with follicular lymphoma, one of the most common types of non-Hodgkin's lymphoma, the fifth most prevalent form of cancer.

Dr Gunnar Riemann, member of the board of management for Bayer, said: "The CHMP's recommendation represents an important milestone for Zevalin."

"This therapy option will provide clinicians with a treatment regimen that truly could help many of their patients to an extended progression-free survival," he added.

25th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics